## Clozapine-Induced Myocarditis and Cardiomyopathy ### Clinical Presentation & Pathophysiology Clozapine is associated with two distinct cardiac complications: | Feature | Myocarditis | Cardiomyopathy | |---------|-----------|----------------| | **Onset** | Early (days to weeks, typically <4 weeks) | Late (months to years) | | **Mechanism** | Immune-mediated inflammation; direct cardiotoxicity | Chronic myocardial damage; oxidative stress | | **Presentation** | Chest pain, dyspnea, fever, elevated troponin | Progressive dyspnea, fatigue, edema | | **Echo findings** | Global hypokinesis, pericardial effusion | Dilated ventricles, reduced EF | | **Incidence** | ~1–2% of clozapine users | ~0.5–1% | | **Prognosis** | Variable; can be fulminant or self-limited | Often progressive; may be irreversible | **Key Point:** This patient's 8-month timeline, cardiomegaly, and dilated cardiomyopathy with EF 28% are consistent with **clozapine-induced cardiomyopathy**, which may have been preceded by unrecognized myocarditis in the early weeks of therapy. ### Risk Factors for Clozapine Cardiotoxicity - Young age (paradoxically; peak incidence 20–40 years) - Female gender - High doses (>300 mg/day) - Rapid dose escalation - Concurrent use of other cardiotoxic agents (e.g., antipsychotics, lithium) - Genetic predisposition (polymorphisms in CYP1A2, TNF-α) ### Diagnostic Workup ```mermaid flowchart TD A[Clozapine-treated patient<br/>with cardiac symptoms]:::outcome --> B[ECG, troponin, BNP]:::action B --> C{Troponin elevated<br/>or ECG changes?}:::decision C -->|Yes| D[Myocarditis likely]:::outcome C -->|No| E[Echocardiography]:::action E --> F{Dilated LV<br/>reduced EF?}:::decision F -->|Yes| G[Cardiomyopathy]:::outcome F -->|No| H[Consider other causes]:::action D --> I[Discontinue clozapine]:::action G --> I I --> J[Cardiac support:<br/>ACE-I, beta-blocker,<br/>diuretics, MRA]:::action J --> K[Cardiology follow-up]:::action ``` **High-Yield:** Baseline ECG and troponin should be obtained *before* starting clozapine. Regular cardiac monitoring (ECG, troponin, BNP, echo) is recommended, especially in the first 4 weeks and if symptoms develop. ### Management Strategy **Key Point:** Clozapine must be discontinued immediately upon diagnosis of myocarditis or cardiomyopathy. 1. **Discontinue clozapine** — do NOT taper; abrupt cessation is safer than continued exposure 2. **Initiate heart failure therapy:** - ACE inhibitor (e.g., lisinopril 10 mg daily, titrate to 20–40 mg) - Beta-blocker (e.g., carvedilol 3.125 mg BID, titrate) - Diuretic (e.g., furosemide 40–80 mg daily) - Aldosterone antagonist (e.g., spironolactone 25 mg daily) if EF <35% 3. **Cardiology referral** for device therapy (ICD/CRT) if EF remains <35% after 3–6 months of optimal medical therapy 4. **Psychiatry re-evaluation:** Consider alternative antipsychotics with lower cardiac risk (aripiprazole, quetiapine, risperidone) after cardiac stabilization **Clinical Pearl:** Some patients with mild myocarditis may recover cardiac function if clozapine is stopped early. However, established cardiomyopathy (EF <35%) is often irreversible, even after drug discontinuation. ### Clozapine Rechallenge: Contraindicated - Absolute contraindication if myocarditis or cardiomyopathy develops - Risk of recurrence is high - Alternative atypicals should be used ### Antipsychotic Choice After Clozapine Discontinuation | Agent | Cardiac Risk | Notes | |-------|--------------|-------| | **Aripiprazole** | Very low | Preferred; minimal cardiac effects | | **Quetiapine** | Low | Acceptable; monitor for orthostasis | | **Risperidone** | Low–moderate | Acceptable; monitor prolactin | | **Olanzapine** | Moderate | Metabolic risk; not ideal | | **Haloperidol** | Low–moderate | Acceptable; risk of QT prolongation | **Warning:** Olanzapine is NOT a safe alternative — it carries metabolic and cardiac risks similar to clozapine.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.